滤泡性淋巴瘤利妥昔单抗维持治疗期间持续性新冠肺炎肺炎及抗SARS-CoV-2抗体未产生 - Suppr

Persistent COVID-19 Pneumonia and Failure to Develop Anti-SARS-CoV-2 Antibodies During Rituximab Maintenance Therapy for Follicular Lymphoma.

作者信息

Yasuda Hajime, Tsukune Yutaka, Watanabe Naoki, Sugimoto Kazuya, Uchimura Ayana, Tateyama Misa, Miyashita Yosuke, Ochi Yusuke, Komatsu Norio

机构信息

Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan.

出版信息

Clin Lymphoma Myeloma Leuk. 2020 Nov;20(11):774-776. doi: 10.1016/j.clml.2020.08.017. Epub 2020 Aug 22.

DOI:10.1016/j.clml.2020.08.017

PMID:32933879

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7442568/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e07/7442568/c19754c47ef5/gr1_lrg.jpg

相似文献

Persistent COVID-19 Pneumonia and Failure to Develop Anti-SARS-CoV-2 Antibodies During Rituximab Maintenance Therapy for Follicular Lymphoma.滤泡性淋巴瘤利妥昔单抗维持治疗期间持续性新冠肺炎肺炎及抗SARS-CoV-2抗体未产生

Clin Lymphoma Myeloma Leuk. 2020 Nov;20(11):774-776. doi: 10.1016/j.clml.2020.08.017. Epub 2020 Aug 22.

A COVID-19 Patient with Repeatedly Undetectable SARS-CoV-2 Antibodies.一名严重急性呼吸综合征冠状病毒2（SARS-CoV-2）抗体多次检测不到的新型冠状病毒肺炎（COVID-19）患者。

J Appl Lab Med. 2020 Nov 1;5(6):1401-1405. doi: 10.1093/jalm/jfaa137.

Duration of serum neutralizing antibodies for SARS-CoV-2: Lessons from SARS-CoV infection.新型冠状病毒血清中和抗体的持续时间：严重急性呼吸综合征冠状病毒感染的经验教训。

J Microbiol Immunol Infect. 2020 Oct;53(5):821-822. doi: 10.1016/j.jmii.2020.03.015. Epub 2020 Mar 25.

Evaluation of SARS-CoV-2 antibodies in 24 patients presenting with chilblains-like lesions during the COVID-19 pandemic.2019冠状病毒病大流行期间24例出现冻疮样病变患者的严重急性呼吸综合征冠状病毒2抗体评估

J Am Acad Dermatol. 2020 Dec;83(6):1753-1755. doi: 10.1016/j.jaad.2020.08.049. Epub 2020 Aug 18.

[Not Available].[无可用内容]。

Rev Med Suisse. 2020 Jun 10;16(697):1220-1221.

SARS-CoV-2 antibody performances: we need better criteria.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）抗体检测性能：我们需要更完善的标准。

Clin Chem Lab Med. 2020 Sep 25;58(12):e303-e305. doi: 10.1515/cclm-2020-1358.

Covid-19 antibody tests: a briefing.新冠病毒-19抗体检测：简报

BMJ. 2020 Jun 24;369:m2284. doi: 10.1136/bmj.m2284.

Cellular immune responses to covid-19.对新冠病毒的细胞免疫反应。

BMJ. 2020 Jul 31;370:m3018. doi: 10.1136/bmj.m3018.

Clinical performances of an ELISA for SARS-CoV-2 antibody assay and correlation with neutralization activity.一种用于严重急性呼吸综合征冠状病毒2（SARS-CoV-2）抗体检测的酶联免疫吸附测定（ELISA）的临床性能及其与中和活性的相关性

Clin Chim Acta. 2020 Nov;510:654-655. doi: 10.1016/j.cca.2020.08.024. Epub 2020 Aug 18.

Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia.慢性淋巴细胞白血病患者的抗严重急性呼吸综合征冠状病毒2抗体反应

Leukemia. 2020 Nov;34(11):3047-3049. doi: 10.1038/s41375-020-01030-2. Epub 2020 Aug 27.

引用本文的文献

Anti-CD20 maintenance strategies to face the challenge of COVID-19 pandemic in follicular lymphoma: results from the R-FolSTOP multicentre Italian study.应对滤泡性淋巴瘤中 COVID-19 大流行挑战的抗 CD20 维持策略：意大利多中心 R-FolSTOP 研究结果

Ann Hematol. 2025 Mar;104(3):1655-1667. doi: 10.1007/s00277-025-06295-0. Epub 2025 Mar 12.

SARS-CoV-2 detection via metagenomic next-generation sequencing of bronchoalveolar lavage fluid/sputum in lymphoma patients receiving B-cell-depleting therapy: a case report of two cases.通过对接受B细胞清除疗法的淋巴瘤患者的支气管肺泡灌洗液/痰液进行宏基因组下一代测序检测严重急性呼吸综合征冠状病毒2：两例病例报告

Front Med (Lausanne). 2025 Feb 13;12:1434340. doi: 10.3389/fmed.2025.1434340. eCollection 2025.

Clinical Features and Prognosis of Patients with COVID-19 and B-Cell Non-Hodgkin Lymphoma.新型冠状病毒肺炎合并B细胞非霍奇金淋巴瘤患者的临床特征与预后

Infect Drug Resist. 2024 Oct 17;17:4501-4510. doi: 10.2147/IDR.S477107. eCollection 2024.

The Outcome of SARS-CoV-2 Infection in Patients with Lymphoma and the Risk Factors for the Development of Pneumonia.淋巴瘤患者感染新型冠状病毒2的结局及肺炎发生的危险因素

Infect Chemother. 2024 Sep;56(3):378-385. doi: 10.3947/ic.2024.0046.

Clinical features of COVID-19 infection in patients with myasthenia gravis: a real-world retrospective study.新冠病毒感染合并重症肌无力患者的临床特征：一项真实世界的回顾性研究。

Front Public Health. 2024 Aug 27;12:1421211. doi: 10.3389/fpubh.2024.1421211. eCollection 2024.

Exposure to obinutuzumab does not affect outcomes of SARS-CoV-2 infection in vaccinated patients with newly diagnosed advanced-stage follicular lymphoma.对于新诊断的晚期滤泡性淋巴瘤的接种疫苗患者，暴露于奥妥珠单抗并不影响其感染SARS-CoV-2的结果。

Br J Haematol. 2024 Dec;205(6):2219-2227. doi: 10.1111/bjh.19661. Epub 2024 Jul 22.

Recurrent Cytokine Storm in SARS-CoV-2 Infected Patients with Hematolymphoid Malignancy: A New Perspective.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染的血液淋巴系统恶性肿瘤患者中反复出现的细胞因子风暴：一个新视角

South Asian J Cancer. 2023 Aug 11;13(2):157-162. doi: 10.1055/s-0043-1761443. eCollection 2024 Apr.

Radiologic Abnormalities in Prolonged SARS-CoV-2 Infection: A Systematic Review.长期严重急性呼吸综合征冠状病毒 2 感染的放射学异常：系统评价。

Korean J Radiol. 2024 May;25(5):473-480. doi: 10.3348/kjr.2023.1149.

Prolonged viral pneumonia and high mortality in COVID-19 patients on anti-CD20 monoclonal antibody therapy.COVID-19 患者接受抗 CD20 单克隆抗体治疗后出现持续性病毒性肺炎和高死亡率。

Eur J Clin Microbiol Infect Dis. 2024 Apr;43(4):723-734. doi: 10.1007/s10096-024-04776-0. Epub 2024 Feb 15.

Case report: Ensitrelvir for treatment of persistent COVID-19 in lymphoma patients: a report of two cases.病例报告：恩赛特韦治疗淋巴瘤患者持续性 COVID-19：两例报告。

Front Immunol. 2024 Jan 25;15:1287300. doi: 10.3389/fimmu.2024.1287300. eCollection 2024.

本文引用的文献

Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies; King's College Hospital experience.血液系统恶性肿瘤的COVID-19患者中SARS-CoV-2 RNA的不良预后和长期持续存在；国王学院医院的经验。

Br J Haematol. 2020 Sep;190(5):e279-e282. doi: 10.1111/bjh.16935. Epub 2020 Aug 10.

Detection of SARS-CoV-2 in Different Types of Clinical Specimens.SARS-CoV-2 在不同类型临床标本中的检测。

JAMA. 2020 May 12;323(18):1843-1844. doi: 10.1001/jama.2020.3786.

The effect of rituximab on vaccine responses in patients with immune thrombocytopenia.利妥昔单抗对免疫性血小板减少症患者疫苗反应的影响。

Blood. 2013 Sep 12;122(11):1946-53. doi: 10.1182/blood-2013-04-494096. Epub 2013 Jul 12.

Rituximab-treated patients have a poor response to influenza vaccination.利妥昔单抗治疗的患者对流感疫苗接种反应不佳。

J Clin Immunol. 2013 Feb;33(2):388-96. doi: 10.1007/s10875-012-9813-x. Epub 2012 Oct 14.

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.利妥昔单抗维持治疗对利妥昔单抗联合化疗后高肿瘤负荷滤泡性淋巴瘤患者的影响（PRIMA）：一项 3 期随机对照试验。

Lancet. 2011 Jan 1;377(9759):42-51. doi: 10.1016/S0140-6736(10)62175-7. Epub 2010 Dec 20.

Rituximab-associated infections.利妥昔单抗相关感染。

Semin Hematol. 2010 Apr;47(2):187-98. doi: 10.1053/j.seminhematol.2010.01.002.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Persistent COVID-19 Pneumonia and Failure to Develop Anti-SARS-CoV-2 Antibodies During Rituximab Maintenance Therapy for Follicular Lymphoma.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献